Biostax (BTAX) 10-Q 16 Aug 21 2021 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2021	Aug. 16, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	000-54933
Entity Registrant Name	IMMUNE THERAPEUTICS, INC.
Entity Central Index Key	0001559356
Entity Tax Identification Number	59-3226705
Entity Incorporation, State or Country Code	FL
Entity Address, Address Line One	2431 Aloma Ave.
Entity Address, Address Line Two	Suite 124
Entity Address, City or Town	Winter Park
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32792
City Area Code	888
Local Phone Number	613-8802
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		481,906

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current Assets:
Cash	$ 23,216	$ 9,971
Total current assets	23,216	9,971
Deposits		200
Total assets	23,216	10,171
Current Liabilities:
Accounts payable	2,583,878	2,562,515
Accrued payroll	3,602,814	3,627,648
Accrued interest	485,915	635,217
Accrued liabilities	280,975	221,057
Undocumented investor advances	140,000
Payables due to related parties	716,011	531,420
Notes payable, net of debt discount	3,070,208	2,844,851
Derivative liability		1,254,444
Total current liabilities	10,879,801	11,677,151
Total liabilities	10,879,801	11,677,152
Commitments and Contingencies
Stockholders’ Deficit:
Common stock – par value $0.0001; 750,000,000 shares authorized; 481,906 and 476,504 shares issued and outstanding respectively	49	48
Additional paid in capital	371,473,810	371,341,120
Stock issuances due	10,303	10,303
Accumulated deficit	(382,340,747)	(383,018,452)
Total stockholders’ deficit	(10,856,585)	(11,666,981)
Total liabilities and stockholders’ deficit	$ 23,216	$ 10,171

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	750,000,000	750,000,000
Common stock, shares issued	481,906	476,504
Common stock, shares outstanding	481,906	476,504

Condensed Consolidated Statemen

Condensed Consolidated Statement of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Operating expenses
Selling, general and administrative	$ 185,284	$ 21,790	$ 324,016	$ 385,427
Research and development expense	3,974	(3,944)	152,667	27,566
Depreciation and amortization expense		160		319
Total operating expense	189,258	18,006	476,683	413,312
Loss from operations	(189,258)	(18,006)	(476,683)	(413,312)
Other income (expense):
Interest expense	(32,131)	(126,964)	(132,535)	(213,149)
Finance charges		(137,397)		(137,397)
Gain on assignment of liabilities	108,693		108,693
Gain/(Loss) on derivative liability valuation		(521,179)	1,178,230	(832,562)
Total other expense	76,562	(785,540)	1,154,388	(1,183,108)
Net income (loss)	(112,696)	(803,546)	677,705	(1,596,420)
Net income (loss) attributable to common stockholders	$ (112,696)	$ (803,546)	$ 677,705	$ (1,596,420)
Basic income (loss) per share attributable to common stockholders	$ (0.23)	$ (1.76)	$ 1.41	$ (3.49)
Diluted earnings (loss) per share attributable to common stockholders	$ (0.23)	$ (1.76)	$ 0.05	$ (3.49)
Basic weighted average number of shares outstanding	481,906	457,578	480,115	457,578
Diluted weighted average number of shares outstanding	481,906	457,578	13,874,667	457,578

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity/(Deficit) (Unaudited) - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Stock to be Issued [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 46	$ 370,908,099	$ 10,303	$ (384,607,069)	$ (13,688,621)
Balance, shares at Dec. 31, 2019	457,578
Net income (loss)				(1,596,420)	(1,596,420)
Ending balance, value at Jun. 30, 2020	$ 46	370,908,099	10,303	(386,203,489)	(15,285,041)
Balance, shares at Jun. 30, 2020	457,578
Beginning balance, value at Dec. 31, 2020	$ 48	371,341,120	10,303	(383,018,452)	(11,666,981)
Balance, shares at Dec. 31, 2020	476,504
Issuance of common stock upon conversion of debt	$ 1	56,479			$ 56,480
Issuance of common stock upon conversion of debt, shares	5,402				5,402
Extinguishment of derivative liability upon conversion of debt		76,211			$ 76,211
Net income (loss)				677,705	677,705
Ending balance, value at Jun. 30, 2021	$ 49	$ 371,473,810	$ 10,303	$ (382,340,747)	$ (10,856,585)
Balance, shares at Jun. 30, 2021	481,906

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net income (loss)	$ 677,705	$ (1,596,420)
Adjustments to reconcile net income (loss) to net cash flows provided by ( used in ) operating activities:
Depreciation		319
Amortization of debt discount	34,789	25,065
Gain on settlement of liabilities	(108,693)
Change in value of derivative	(1,178,230)	832,562
Finance charges		137,397
Changes in operating assets and liabilities:
Deposits	200
Accounts payable	130,053	120,889
Accrued payroll	(24,834)	74,236
Accrued interest	97,746	198,342
Accrued liabilities	13,418	84,998
Due to related parties	231,091	27,954
Net cash (used in) operating activities	(126,755)	(94,658)
CASH FLOWS FROM INVESTING ACTIVITIES
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from undocumented investor advances	140,000
Proceeds from issuance of notes payable		135,000
Net cash provided by financing activities	140,000	135,000
Net increase in cash and cash equivalents	13,245	40,342
Cash and cash equivalents at beginning of period	9,971	4,925
Cash and cash equivalents at end of period	23,216	45,267
SUPPLEMENTAL DISCLOSURE OF NON-CASH ACTIVITIES:
Conversion of debt and accrued interest to common stock	56,480
Reclassification to notes payable from accrued interest	243,568
Debt discount on notes payable and warrant		$ 135,000

Company Overview

Company Overview	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Company Overview	1. Company Overview Immune Therapeutics Inc. (the “Company” or “IMUN”) is a Florida corporation trading on the OTC-Pink market. The Company is a drug development and commercialization company. We identify, evaluate, and seek to acquire technologies in the medical device and drug development sectors with the intent to further develop them and move them to commercialization. Such commercialization efforts include sale, licensing and go to market strategies. During 2020 as described herein, the Company executed two such licenses; one to Cytocom, Inc. (“Cytocom”) and one to Forte Animal Health, Inc. (“Forte”). The Company’s strategy has been limited due to lack of capital. Management is seeking to secure new investment capital with which to continue to pursue the Company’s strategy. There is no guaranty that the Company will be successful in securing additional capital. Going Concern As of June 30, 2021, the Company had $ 23,216 in cash on hand, negative working capital of $ 10,856,585 and a stockholders’ deficit of $ 10,856,585 . For the six months ended June 30, 2021, the Company reported net income attributable to common shareholders of $ 677,705 . For the three months ended June 30, 2021, the Company reported a net loss attributable to common shareholders of $ 112,696 . During the three and six months ended June 30, 2020, the Company reported a net loss attributable to common shareholders of $ 803,546 and $ 1,596,420 , respectively. Included in net income for the six months ended June 30, 2021, are non-cash gains of $ 1,178,230 108,693 1,178,230 108,693 Historically the Company has relied on the funding of operations through private equity financings and management expects operating losses and negative cash flows to continue at more significant levels in the future. As the Company continues to incur losses, transition to profitability is dependent upon the successful development, approval, and commercialization of its current or future product candidates as they become available and the achievement of a level of revenues adequate to support the Company’s cost structure. The Company may never achieve profitability, and unless and until it does, the Company will continue to need to raise additional cash. Management intends to fund future operations through additional private or public debt or equity offerings and may seek additional capital through arrangements with strategic partners or from other sources. Working capital at June 30, 2021 is not sufficient to meet the cash requirements to fund planned operations through the next twelve months without additional sources of cash. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying financial statements have been prepared assuming that the Company will continue as a going concern and do not include adjustments that might result from the outcome of this uncertainty. This basis of accounting contemplates the recovery of the Company’s assets and the satisfaction of liabilities in the normal course of business. If the Company is unable to secure new working capital, other alternatives strategies will be required. There can be no guaranties that the Company will be successful in: ● Executing its restructuring plan ● Securing adequate capital to continue operations. ● Identifying and acquiring assets for future development.

Summary of Significant Accounti

Summary of Significant Accounting Policies	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The condensed consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been omitted. However, in the opinion of management, all adjustments (which include only normal recurring adjustments, unless otherwise indicated) necessary to present fairly the financial position and results of operations for the periods presented have been made. The results for interim periods are not necessarily indicative of trends or of results to be expected for the full year. These financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2020 (including the notes thereto) set forth in Form 10- K. We have identified the policies below as critical to our business operations and the understanding of its results of operations. The Company’s senior management has reviewed these critical accounting policies and related disclosures with the Company’s Board of Directors. The impact and any associated risks related to these policies on our business operations are discussed throughout this section where such policies affect our reported and expected financial results. Shares Issued and Outstanding The Company’s shareholders approved a 1,000:1 reverse stock split in October 2019. The action was filed with the State of Florida during the first quarter of 2020 at which time all current and historical financial reporting was restated to reflect the impact of the reverse split on per share and warrant grant disclosures. On May 6, 2021, the Company received approval from the Financial Industry Regulatory Authority (“FINRA”). All share amounts for all periods have been retroactively adjusted to reflect this reverse split. Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates. Cash, Cash Equivalents, and Short-Term Investments The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value . Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $ 250,000 Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making. Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “Financial Instruments”, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments. Cash, cash equivalents and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of notes payable also approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes. Derivative Financial Instruments FASB ASC 820, Fair Value Measurements Research and Development Costs Research and development costs are charged to expense as incurred and are typically comprised of expenses associated with advancing the commercialization of our technologies. Expenses recognized in the quarter ended June 30, 2021 consisted of amounts paid to consultants for patent related activities. Income Taxes The Company follows ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of June 30, 2021 and 2020, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of June 30, 2021 and 2020, the Company has no Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors based on estimated fair values equaling either the market value of the shares issued, or the value of consideration received, whichever is more readily determinable. Generally, the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 718, “ Compensation-Stock Compensation The Company did no Net Income (Loss) per Share The Company’s potentially dilutive securities, common stock warrants, have been included in the computation of diluted net income per share for the six-month period ended June 30, 2021. Net income per share for the six-month period ended June 30, 2021 was calculated by dividing the net income by the weighted-average number of common shares outstanding for the period determined using the treasury-stock method and the if-converted method. Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. For the three-month period ended June 30, 2021 and for the three- and six-month periods ended June 30, 2020, the potentially dilutive securities were excluded from the computation of diluted loss per share as the effect would be to reduce the net loss per common share. Therefore, the weighted-average common stock outstanding used to calculate both basic and diluted net loss per share is the same for these loss periods. A reconciliation of the weighted average shares outstanding used in basic and diluted earnings per share computation is as follows: Schedule of Antidilutive Securities Net Income Weighted Average Per Share Amount Basic EPS Income available to common stockholders $ 677,705 480,115 $ 1.41 Diluted EPS Assumed exercise of outstanding warrants 13,397,552 $ 0.05 Income available to common stockholders $ 677,705 13,874,667 Recent Accounting Standards The Company has reviewed the accounting pronouncements issued by the Financial Accounting Standards Board during the first half of 2021. Applicable pronouncements will be adopted by the Company in accordance with the accounting guidance and definition. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.

Notes payable

Notes payable	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Notes payable	3. Notes payable As of June 30, 2021 and December 31, 2020, the Company had $ 1,677,275 1,639,275 During the first quarter of 2021, the Company issued 5,402 10.40 53,000 3,480 During the first quarter of 2020, the Company issued a $ 53,000 promissory note. The noteholder subsequently converted the principal and all accrued interest on these notes in the amount of $ 3,180 in October 2020. The Company issued 6,893 shares of common stock at an average price per share of $ 8.15 in connection with this conversion. A summary of Notes Payable at June 30, 2021 and December 31, 2020 follows. Schedule of Notes Payable June 30, 2021 December 31, 2020 Promissory notes issued between December 2014 and January 2015. The notes accrues interest at 10 5 36 $ 70,000 $ 70,000 Promissory notes issued between February 2016 and July 2018 with interest rates ranging from 2 10 February 2017 and November 2018 149,500 149,500 Promissory notes issued in the fourth quarter of 2016, accrue interest at 2 5 606,500 606,500 Promissory notes issued in 2017 accrue interest at 2 5 205,000 205,000 Promissory notes issued in May 2017 accrue interest at 2 5 150,000 150,000 Promissory notes issued in the third quarter of 2017 accrue interest at 2 5 116,800 116,800 A promissory note for $ 425,000 70,000 22 454,032 697,600 - 454,032 Promissory notes issued in December 2017 accrue interest at 2 5 105,500 105,500 Promissory notes issued in January 2018 accrue interest at 2 5 May 2018 and January 2019 47,975 47,975 Promissory notes issued from March 2018 through June 2018 accrue interest at 2 5 July and October 2018 5 65,000 65,000 Promissory notes issued in the second quarter of 2018 accrue interest at 2 5 November 2018 and August 2019 0.05 118,000 118,000 Promissory notes issued in the third and fourth quarters of 2018 accrue interest at 2 5 November 2019 5 40 323,855 323,855 Promissory note issued to Global Reverb Corp. in the first quarter of 2019 accrues interest at 2 5 July 2019 5 23,000 23,000 Promissory note issued in the first quarter of 2019, accrues interest at 6 February 2020 231,478 231,478 Promissory note issued in April 2019 accrues interest at 2 5 July 2019 5 10,000 10,000 Promissory note issued in October 2019 for the settlement of outstanding debt in the same amount. The note accrues interest at 15 5 1,875 April 30, 2021 150,000 150,000 Promissory note issued in the third quarter of 2020 accrues interest at 12 August 2021 54,312 5,402 February 2021 - 53,000 Promissory notes issued in the first quarter of 2021 in connection with a Note Purchase Agreement with a previous note holder. The new notes reflect all principal, interest and penalties associated with the original instrument. These notes accrue interest at 5 7 348,800 March 2022 697,600 - 3,070,208 2,879,640 Less: Original issue discount on notes payable and warrants issued with notes. - (34,789 ) $ 3,070,208 $ 2,844,851 As of June 30, 2021 and December 31, 2020, the Company had $ 485,915 635,217

Derivative Liabilities

Derivative Liabilities	6 Months Ended
	Jun. 30, 2021
Derivative Liabilities
Derivative Liabilities	4 Derivative Liabilities As of June 30, 2021, and December 31, 2020, the fair value of the outstanding derivative liabilities was zero 1,254,444 During the first quarter of 2021, the Company entered into a Note Exchange Agreement with a noteholder that resulted in the issuance of new non-convertible promissory notes of $ 697,600 1,200,129 Also during the first quarter of 2021, the Company issued 5,402 common shares in connection with a noteholder’s election to convert $ 56,480 in principal and interest to common shares. The Company recognized $ 21,899 for the change in fair market value on related derivative liability prior to the conversion and derecognized $ 76,211 in derivative liabilities. The Company determines the fair values of its financial instruments based on the fair value hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. The following three levels of inputs may be used to measure fair value: ● Level 1 Quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. ● Level 2 Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. ● Level 3 Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. A reconciliation of changes in the fair value of derivative liabilities classified as Level 3 in the fair value hierarchy follows: Schedule of Reconciliation of Changes in the Fair Value of Derivative Liabilities Conversion option derivative liability Balance December 31, 2020 $ 1,254,441 Change in fair value 21,899 Settlement of liability upon debt exchange and conversion (1,276,340 ) Balance June 30, 2021 $ -

Capital Structure _ Common Stoc

Capital Structure – Common Stock and Stock Purchase Warrants	6 Months Ended
	Jun. 30, 2021
Capital Structure Common Stock And Stock Purchase Warrants
Capital Structure – Common Stock and Stock Purchase Warrants	5 Capital Structure – Common Stock and Stock Purchase Warrants Each holder of common stock is entitled to vote on all matters and is entitled to one vote for each share held. No holder of shares of stock of any class shall be entitled, as a matter of right, to subscribe for or purchase or receive any part of any new or additional issue of shares of stock of any class, or of securities convertible into shares of stock or any class, whether now hereafter authorized or whether issued for money, for consideration other than money, or by way of dividend. Stock Warrants During the six months ended June 30, 2021 and June 30, 2020, no no The following is a summary of outstanding common stock warrants at June 30, 2021. Schedule of Outstanding Common Stock Warrants Expiration Date Number of Shares Exercise Price Remaining Life (years) Third Quarter 2021 5,167 $ 30 200 .50 Fourth Quarter 2021 300 $ 100 .75 First Quarter 2022 150 $ 200 1.00 Second Quarter 2022 1,750 $ 150 1.25 Third Quarter 2022 1,650 $ 50 100 1.50 Fourth Quarter 2022 9,811 $ 80 290 1.75 First Quarter 2023 1,204,000 $ 5 40 2.00 Second Quarter 2023 802,000 $ 5 200 2.25 Third Quarter 2023 7,521,500 $ 5 100 2.50 Fourth Quarter 2023 6,024,300 $ 0.20 - 5 2.75 First Quarter 2024 3,660,000 $ 5 3.00 Second Quarter 2024 800,000 $ 5 3.25 Third Quarter 2028 3,000 $ 70 7.50 Second Quarter 2032 28,995 $ 10 70 11.25 20,062,623 $ 5 200 The following is a summary of outstanding stock warrant activity for the six months ended June 30, 2021: Schedule of Outstanding Stock Warrants Number of Shares Exercise Price Weighted Average Price Warrants as of December 31, 2020 20,081,035 $ 0.05 200 $ 0.68 Issued - - - Expired and forfeited (18,412 ) $ 14 200 $ 152.68 Exercised - - - Warrants as of June 30, 2021 20,062,623 $ 0.05 200 $ 0.54

Income Taxes _ Results of Opera

Income Taxes – Results of Operations	6 Months Ended
	Jun. 30, 2021
Income Tax Disclosure [Abstract]
Income Taxes – Results of Operations	6. Income Taxes – Results of Operations There was no The Company’s effective tax rate is affected by recurring items, such as tax rates in foreign jurisdictions and the relative amount of income we earn in jurisdictions. This rate may also be affected by discrete items that may occur in any given year but are not consistent from year to year. For U.S. federal purposes the corporate statutory income tax rate was 21

Licenses Agreements

Licenses Agreements	6 Months Ended
	Jun. 30, 2021
Licenses Agreements
Licenses Agreements	7. Licenses Agreements Due to the Company’s need to generate short term cash flow to fund operations, the Company sublicensed its remaining technology to Forte and Cytocom Inc. as detailed below. The Company is currently seeking to acquire pharmaceutical and medical device products, technology and/or intellectual property that it can incubate for future commercialization Forte Animal Health, Inc. On February 27, 2020, the Company approved and entered into a license agreement (the “License Agreement”) with Forte Animal Health Inc. (“Forte”). Under the License Agreement, the Company granted Forte an exclusive license to develop and commercialize pharmaceutical products consisting of Lodonal and MENK for use in veterinary applications for all indications world-wide. Milestone payments and royalties are defined in the agreement based on development and royalties are based on sales during the license period. The Initial License Fee includes the assumption of certain Company defaulted Notes and other liabilities. Forte will assume a minimum of IMUN defaulted debt and to assume certain additional obligations of the Company. The note holders and vendors associated with the assigned liabilities have not yet assigned their rights to Forte. Consideration for February 28, 2020 License to Forte (as amended July 8, 2021) Schedule of Consideration Consideration / Assumption of: Notes in Default $ 1,742,868 Accounts payable and accruals 245,692 Past Due Employee Obligations 1,016,648 Total Consideration to be Recognize Upon Execution $ 3,005,208 The documentation and sign off, of the Forte license, have yet to be executed by the individual lenders that will be required to provide their approval for the transfer of these notes. As such the accompanying financial statements do not reflect any gain on sale. Until such time as the transaction is completed Forte does not have clear title and interest to the veterinary rights. Forte has agreed to make payments to the Company in connection with this agreement as follows: ● Initial License Fee, upon the assignment of certain Company Notes Payable. ● Development Milestone Payments upon the occurrence of the identified events, one-time, non-creditable, non-refundable milestone payments of $ 100,000 ● Commercial Milestone Payments upon reaching the mutually agreed aggregate net sales. Forte will pay one-time, non-creditable, non-refundable milestone payments to be negotiated and addressed in a separate Amendment later. ● Royalties during the royalty term (generally 15 Schedule of Royalty Rate Annual Sales of Royalty Qualifying Licensed Products Royalty Rate <$500,000,000 2 % 500,000,000 to < $1,000,000,000 4 % > $1,000,000,000) 6 % To date the Company has not received any payments under the terms of this agreement. Cytocom On May 13, 2020, the Company and Cytocom entered into Amendment to The Second Amendment to The License Agreement (“Third Amendment”) that was effective December 31, 2018. The sublicense provides Cytocom with the Company’s previously licensed rights for LDN and MENK in Emerging Markets. Original terms for consideration for the sublicense were not finalized until August 12, 2020, at which time Cytocom and the Company signed a letter agreement in which Cytocom agreed to assume a combination of defaulted notes plus certain other liabilities. Such terms were amended and the Company agreed to transfer all the rights, title, and interest to Cytocom in technology licensed from Penn State Research Foundation in exchange for Cytocom assuming all past due and future obligations under the Penn State license. While the Company formalized the agreement to deconsolidate Penn State University, a vendor of the Company, did not consent to assign the payables to Cytocom. As of June 30, 2021, the Company had outstanding accounts payable balances of $ 372,732 421,048 In the third quarter of 2020, the Company received a Notice of Default (“Notice”) from Cytocom relating to the sublicensing transaction. The Company disputes the validity of the Notice on the basis that Cytocom has failed to execute on their consideration for the license. On July 20, 2021 the Notice of Default was rescinded. On July 20, 2021, Cytocom and the Company agreed to modify the terms of the original sublicense. The renegotiated terms are presented below. The Notes in Default portion of the transaction was fully executed in the third quarter of 2020 with the transfer of the notes upon the creditors signoff. The Company recognized a gain upon the assignment of these notes in the third quarter of 2020. Cytocom has not completed the assumption of the remaining liabilities. Consideration for May 13, 2020 License to Cytocom (as amended July 20, 2021) Consideration / Assumption of: Notes in Default $ 3,302,209 Accounts payable and accruals 230,000 Past Due Employee Obligations 1,110,567 Total anticipated Consideration $ 4,642,776 Recognized through December 31, 2020 (3,302,209 ) To Be Recognized upon Execution $ 1,340,567 At June 30, 2021, the Company has an equity interest of approximately 13.3% in Cytocom. In connection with the May 1, 2018 “Restated Agreement” with Cytocom, the Company no longer has ongoing obligations to pay for costs in connection with the assets of Cytocom. Accordingly, effective May 1, 2018, the Company deconsolidated Cytocom. The Company uses the equity method to account for its retained interest in Cytocom. As the balance of the Company’s investment in Cytocom has been zero since 2018, no losses have been recognized during the six months ended June 30, 2021. On July 27, 2021, Cytocom reported the completion of its previously announced merger with Cleveland BioLabs, Inc. (“CBLI”) The shares of Cytocom were exchanged for shares of CBLI in connection with this transaction. The Company will use the Fair Value Method of accounting to measure the carrying value of these share beginning in the third quarter of 2021.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The condensed consolidated financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been omitted. However, in the opinion of management, all adjustments (which include only normal recurring adjustments, unless otherwise indicated) necessary to present fairly the financial position and results of operations for the periods presented have been made. The results for interim periods are not necessarily indicative of trends or of results to be expected for the full year. These financial statements should be read in conjunction with the financial statements of the Company for the year ended December 31, 2020 (including the notes thereto) set forth in Form 10- K. We have identified the policies below as critical to our business operations and the understanding of its results of operations. The Company’s senior management has reviewed these critical accounting policies and related disclosures with the Company’s Board of Directors. The impact and any associated risks related to these policies on our business operations are discussed throughout this section where such policies affect our reported and expected financial results.
Shares Issued and Outstanding	Shares Issued and Outstanding The Company’s shareholders approved a 1,000:1 reverse stock split in October 2019. The action was filed with the State of Florida during the first quarter of 2020 at which time all current and historical financial reporting was restated to reflect the impact of the reverse split on per share and warrant grant disclosures. On May 6, 2021, the Company received approval from the Financial Industry Regulatory Authority (“FINRA”). All share amounts for all periods have been retroactively adjusted to reflect this reverse split.
Use of Estimates	Use of Estimates The preparation of the Company’s financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from such estimates.
Cash, Cash Equivalents, and Short-Term Investments	Cash, Cash Equivalents, and Short-Term Investments The Company considers all highly liquid investments with original maturities at the date of purchase of three months or less to be cash equivalents. Cash and cash equivalents include bank demand deposits, marketable securities with maturities of three months or less at purchase, and money market funds that invest primarily in certificates of deposits, commercial paper and U.S. government and U.S. government agency obligations. Cash equivalents are reported at fair value .
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash and cash equivalents. The Company is exposed to credit risk, subject to federal deposit insurance, in the event of a default by the financial institutions holding its cash and cash equivalents to the extent of amounts recorded on the condensed consolidated balance sheets. The cash accounts are insured by the Federal Deposit Insurance Corporation up to $ 250,000
Segment and Geographic Information	Segment and Geographic Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one operating segment and does not segment the business for internal reporting or decision making.
Fair Value of Financial Instruments	Fair Value of Financial Instruments In accordance with the reporting requirements of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 825, “Financial Instruments”, the Company calculates the fair value of its assets and liabilities which qualify as financial instruments under this standard and includes this additional information in the notes to the financial statements when the fair value is different than the carrying value of those financial instruments. Cash, cash equivalents and accounts payable are accounted for at cost which approximates fair value due to the relatively short maturity of these instruments. The carrying value of notes payable also approximate fair value since they bear market rates of interest and other terms. None of these instruments are held for trading purposes.
Derivative Financial Instruments	Derivative Financial Instruments FASB ASC 820, Fair Value Measurements
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred and are typically comprised of expenses associated with advancing the commercialization of our technologies. Expenses recognized in the quarter ended June 30, 2021 consisted of amounts paid to consultants for patent related activities.
Income Taxes	Income Taxes The Company follows ASC Topic 740, Income Taxes, which requires recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred tax assets and liabilities are based on the differences between the financial statements and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The standard addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC Topic 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the tax authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than fifty percent likelihood of being realized upon ultimate settlement. ASC Topic 740 also provides guidance on de-recognition, classification, interest and penalties on income taxes, accounting in interim periods and requires increased disclosures. At the date of adoption, and as of June 30, 2021 and 2020, the Company does not have a liability for unrecognized tax uncertainties. The Company’s policy is to record interest and penalties on uncertain tax positions as income tax expense. As of June 30, 2021 and 2020, the Company has no
Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration	Stock-Based Compensation and Issuance of Stock for Non-Cash Consideration The Company measures and recognizes compensation expense for all share-based payment awards made to employees and directors based on estimated fair values equaling either the market value of the shares issued, or the value of consideration received, whichever is more readily determinable. Generally, the non-cash consideration pertains to services rendered by consultants and others and has been valued at the fair value of the Company’s common stock at the date of the agreement. The Company’s accounting policy for equity instruments issued to consultants and vendors in exchange for goods and services follows the provisions of ASC Topic 718, “ Compensation-Stock Compensation The Company did no
Net Income (Loss) per Share	Net Income (Loss) per Share The Company’s potentially dilutive securities, common stock warrants, have been included in the computation of diluted net income per share for the six-month period ended June 30, 2021. Net income per share for the six-month period ended June 30, 2021 was calculated by dividing the net income by the weighted-average number of common shares outstanding for the period determined using the treasury-stock method and the if-converted method. Basic net loss per share is calculated by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. For the three-month period ended June 30, 2021 and for the three- and six-month periods ended June 30, 2020, the potentially dilutive securities were excluded from the computation of diluted loss per share as the effect would be to reduce the net loss per common share. Therefore, the weighted-average common stock outstanding used to calculate both basic and diluted net loss per share is the same for these loss periods. A reconciliation of the weighted average shares outstanding used in basic and diluted earnings per share computation is as follows: Schedule of Antidilutive Securities Net Income Weighted Average Per Share Amount Basic EPS Income available to common stockholders $ 677,705 480,115 $ 1.41 Diluted EPS Assumed exercise of outstanding warrants 13,397,552 $ 0.05 Income available to common stockholders $ 677,705 13,874,667
Recent Accounting Standards	Recent Accounting Standards The Company has reviewed the accounting pronouncements issued by the Financial Accounting Standards Board during the first half of 2021. Applicable pronouncements will be adopted by the Company in accordance with the accounting guidance and definition. Management does not believe the adoption of any of these accounting pronouncements has had or will have a material impact on the Company’s consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Schedule of Antidilutive Securities	A reconciliation of the weighted average shares outstanding used in basic and diluted earnings per share computation is as follows: Schedule of Antidilutive Securities Net Income Weighted Average Per Share Amount Basic EPS Income available to common stockholders $ 677,705 480,115 $ 1.41 Diluted EPS Assumed exercise of outstanding warrants 13,397,552 $ 0.05 Income available to common stockholders $ 677,705 13,874,667

Notes payable (Tables)

Notes payable (Tables)	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
Schedule of Notes Payable	A summary of Notes Payable at June 30, 2021 and December 31, 2020 follows. Schedule of Notes Payable June 30, 2021 December 31, 2020 Promissory notes issued between December 2014 and January 2015. The notes accrues interest at 10 5 36 $ 70,000 $ 70,000 Promissory notes issued between February 2016 and July 2018 with interest rates ranging from 2 10 February 2017 and November 2018 149,500 149,500 Promissory notes issued in the fourth quarter of 2016, accrue interest at 2 5 606,500 606,500 Promissory notes issued in 2017 accrue interest at 2 5 205,000 205,000 Promissory notes issued in May 2017 accrue interest at 2 5 150,000 150,000 Promissory notes issued in the third quarter of 2017 accrue interest at 2 5 116,800 116,800 A promissory note for $ 425,000 70,000 22 454,032 697,600 - 454,032 Promissory notes issued in December 2017 accrue interest at 2 5 105,500 105,500 Promissory notes issued in January 2018 accrue interest at 2 5 May 2018 and January 2019 47,975 47,975 Promissory notes issued from March 2018 through June 2018 accrue interest at 2 5 July and October 2018 5 65,000 65,000 Promissory notes issued in the second quarter of 2018 accrue interest at 2 5 November 2018 and August 2019 0.05 118,000 118,000 Promissory notes issued in the third and fourth quarters of 2018 accrue interest at 2 5 November 2019 5 40 323,855 323,855 Promissory note issued to Global Reverb Corp. in the first quarter of 2019 accrues interest at 2 5 July 2019 5 23,000 23,000 Promissory note issued in the first quarter of 2019, accrues interest at 6 February 2020 231,478 231,478 Promissory note issued in April 2019 accrues interest at 2 5 July 2019 5 10,000 10,000 Promissory note issued in October 2019 for the settlement of outstanding debt in the same amount. The note accrues interest at 15 5 1,875 April 30, 2021 150,000 150,000 Promissory note issued in the third quarter of 2020 accrues interest at 12 August 2021 54,312 5,402 February 2021 - 53,000 Promissory notes issued in the first quarter of 2021 in connection with a Note Purchase Agreement with a previous note holder. The new notes reflect all principal, interest and penalties associated with the original instrument. These notes accrue interest at 5 7 348,800 March 2022 697,600 - 3,070,208 2,879,640 Less: Original issue discount on notes payable and warrants issued with notes. - (34,789 ) $ 3,070,208 $ 2,844,851

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	6 Months Ended
	Jun. 30, 2021
Derivative Liabilities
Schedule of Reconciliation of Changes in the Fair Value of Derivative Liabilities	A reconciliation of changes in the fair value of derivative liabilities classified as Level 3 in the fair value hierarchy follows: Schedule of Reconciliation of Changes in the Fair Value of Derivative Liabilities Conversion option derivative liability Balance December 31, 2020 $ 1,254,441 Change in fair value 21,899 Settlement of liability upon debt exchange and conversion (1,276,340 ) Balance June 30, 2021 $ -

Capital Structure _ Common St_2

Capital Structure – Common Stock and Stock Purchase Warrants (Tables)	6 Months Ended
	Jun. 30, 2021
Capital Structure Common Stock And Stock Purchase Warrants
Schedule of Outstanding Common Stock Warrants	The following is a summary of outstanding common stock warrants at June 30, 2021. Schedule of Outstanding Common Stock Warrants Expiration Date Number of Shares Exercise Price Remaining Life (years) Third Quarter 2021 5,167 $ 30 200 .50 Fourth Quarter 2021 300 $ 100 .75 First Quarter 2022 150 $ 200 1.00 Second Quarter 2022 1,750 $ 150 1.25 Third Quarter 2022 1,650 $ 50 100 1.50 Fourth Quarter 2022 9,811 $ 80 290 1.75 First Quarter 2023 1,204,000 $ 5 40 2.00 Second Quarter 2023 802,000 $ 5 200 2.25 Third Quarter 2023 7,521,500 $ 5 100 2.50 Fourth Quarter 2023 6,024,300 $ 0.20 - 5 2.75 First Quarter 2024 3,660,000 $ 5 3.00 Second Quarter 2024 800,000 $ 5 3.25 Third Quarter 2028 3,000 $ 70 7.50 Second Quarter 2032 28,995 $ 10 70 11.25 20,062,623 $ 5 200
Schedule of Outstanding Stock Warrants	The following is a summary of outstanding stock warrant activity for the six months ended June 30, 2021: Schedule of Outstanding Stock Warrants Number of Shares Exercise Price Weighted Average Price Warrants as of December 31, 2020 20,081,035 $ 0.05 200 $ 0.68 Issued - - - Expired and forfeited (18,412 ) $ 14 200 $ 152.68 Exercised - - - Warrants as of June 30, 2021 20,062,623 $ 0.05 200 $ 0.54

Licenses Agreements (Tables)

Licenses Agreements (Tables)	6 Months Ended
	Jun. 30, 2021
Licenses Agreements
Schedule of Consideration	Consideration for February 28, 2020 License to Forte (as amended July 8, 2021) Schedule of Consideration Consideration / Assumption of: Notes in Default $ 1,742,868 Accounts payable and accruals 245,692 Past Due Employee Obligations 1,016,648 Total Consideration to be Recognize Upon Execution $ 3,005,208 Consideration for May 13, 2020 License to Cytocom (as amended July 20, 2021) Consideration / Assumption of: Notes in Default $ 3,302,209 Accounts payable and accruals 230,000 Past Due Employee Obligations 1,110,567 Total anticipated Consideration $ 4,642,776 Recognized through December 31, 2020 (3,302,209 ) To Be Recognized upon Execution $ 1,340,567
Schedule of Royalty Rate	Schedule of Royalty Rate Annual Sales of Royalty Qualifying Licensed Products Royalty Rate <$500,000,000 2 % 500,000,000 to < $1,000,000,000 4 % > $1,000,000,000) 6 %

Company Overview (Details Narra

Company Overview (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash	$ 23,216		$ 23,216
Working capital	10,856,585		10,856,585
Stockholders equity	10,856,585	$ 15,285,041	10,856,585	$ 15,285,041	$ 11,666,981	$ 13,688,621
Net loss attributable to common shareholders	112,696	803,546	(677,705)	1,596,420
Non-cash gain			1,178,230
Write-off derivative			108,693
Derivative liability		$ (521,179)	1,178,230	$ (832,562)
Vendor payables	$ 108,693		$ 108,693

Schedule of Antidilutive Securi

Schedule of Antidilutive Securities (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Accounting Policies [Abstract]
Income available to common stockholders	$ (112,696)	$ (803,546)	$ 677,705	$ (1,596,420)
Weighted average common shares, basic	481,906	457,578	480,115	457,578
Basic earnings per share	$ (0.23)	$ (1.76)	$ 1.41	$ (3.49)
Assumed exercise of outstanding warrants, shares			13,397,552
Earnings per share exercise of warrants			$ 0.05
Income available to common stockholders			$ 677,705
Weighted Average Number Diluted Shares Outstanding Adjustment	481,906	457,578	13,874,667	457,578

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Oct. 31, 2019	Jun. 30, 2021	Jun. 30, 2020
Accounting Policies [Abstract]
Reverse stock split	1,000:1
Cash at federal deposit		$ 250,000
Unrecognized tax benefits, income tax penalties and interest accrued		0	$ 0
Stock-based compensation		$ 0	$ 0

Notes Payable - Schedule of Not

Notes Payable - Schedule of Notes Payable (Details) (Parenthetical)

Oct. 31, 2019USD ($)

Apr. 30, 2019$ / shares

Jan. 31, 2018

Jan. 31, 2015Installments

Mar. 31, 2021USD ($)

Sep. 30, 2020USD ($)shares

Mar. 31, 2019$ / shares

Dec. 31, 2018$ / shares

Jun. 30, 2018$ / shares

Jun. 30, 2018$ / shares

Jul. 31, 2018

Jun. 30, 2021USD ($)$ / shares

Dec. 31, 2020USD ($)

Dec. 31, 2017

Oct. 31, 2017USD ($)

Sep. 30, 2017

May 31, 2017

Dec. 31, 2016

Jan. 15, 2015

Short-term Debt [Line Items]

Note payable

$ 3,070,208

$ 2,844,851

Minimum [Member]

Short-term Debt [Line Items]

Warrant exercise price per share | $ / shares

$ 5

Maximum [Member]

Short-term Debt [Line Items]

Warrant exercise price per share | $ / shares

$ 200

Notes Payable One [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

10.00%

Debt penalty percentage

0.05

Number of installments | Installments

36

Notes Payable Two [Member] | Lenders [Member]

Short-term Debt [Line Items]

Debt instrument maturity date description

February 2017 and November 2018

Notes Payable Two [Member] | Lenders [Member] | Minimum [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Notes Payable Two [Member] | Lenders [Member] | Maximum [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

10.00%

Notes Payable Three [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt penalty percentage

0.05

Notes Payable Four [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt penalty percentage

0.05

Notes Payable Five [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

200.00%

Debt penalty percentage

0.05

Notes Payable Six [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

200.00%

Debt penalty percentage

0.05

Notes Payable Seven [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

22.00%

Note payable

$ 425,000

Original issuance discount

70,000

Notes Payable Seven [Member] | Note Purchase Agreement [Member]

Short-term Debt [Line Items]

Note payable

454,032

Principal amount

$ 697,600

Notes Payable Eight [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt penalty percentage

0.05

Notes Payable Nine [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt penalty percentage

0.05

Debt instrument maturity date description

May 2018 and January 2019

Notes Payable Ten [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

200.00%

200.00%

Debt penalty percentage

0.05

0.05

Debt instrument maturity date description

July and October 2018

Warrant exercise price per share | $ / shares

$ 5

$ 5

Notes Payable Eleven [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

2.00%

2.00%

Debt penalty percentage

0.05

0.05

Debt instrument maturity date description

November 2018 and August 2019

Warrant exercise price per share | $ / shares

$ 0.05

$ 0.05

Notes Payable Twelve [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt penalty percentage

0.05

Debt instrument maturity date description

November 2019

Notes Payable Twelve [Member] | Minimum [Member]

Short-term Debt [Line Items]

Warrant exercise price per share | $ / shares

$ 5

Notes Payable Twelve [Member] | Maximum [Member]

Short-term Debt [Line Items]

Warrant exercise price per share | $ / shares

$ 40

Notes Payable Thirteen [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt penalty percentage

0.05

Debt instrument maturity date description

July 2019

Notes Payable Fifteen [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

2.00%

Debt penalty percentage

0.05

Debt instrument maturity date description

July 2019

Warrant exercise price per share | $ / shares

$ 5

$ 5

Notes Payable Fourteen [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

6.00%

Debt instrument maturity date description

February 2020

Notes Payable Sixteen [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

15.00%

Debt penalty percentage

0.05

Debt instrument maturity date description

April 30, 2021

Debt instrument, periodic payment, principal

$ 1,875

Notes Payable Seventeen [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

12.00%

Debt instrument maturity date description

August 2021

Derivative liability

$ 54,312

Debt converted shares | shares

5,402

Notes Payable Eightteen [Member]

Short-term Debt [Line Items]

Percentage of interest rate per annum

5.00%

Debt penalty percentage

0.07

Debt instrument maturity date description

March 2022

Notes Payable Eightteen [Member] | Note Purchase Agreement [Member]

Short-term Debt [Line Items]

Principal amount

$ 348,800

Schedule of Notes Payable (Deta

Schedule of Notes Payable (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020	Apr. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Jun. 30, 2018	Oct. 31, 2017
Short-term Debt [Line Items]
Total	$ 3,070,208	$ 2,879,640
Less: Original issue discount on notes payable and warrants issued with notes		(34,789)
Notes payable	$ 3,070,208	2,844,851
Maximum [Member]
Short-term Debt [Line Items]
Warrant exercise price per share	$ 200
Notes Payable One [Member]
Short-term Debt [Line Items]
Total	$ 70,000	70,000
Notes Payable Two [Member]
Short-term Debt [Line Items]
Total	149,500	149,500
Notes Payable Three [Member]
Short-term Debt [Line Items]
Total	606,500	606,500
Notes Payable Four [Member]
Short-term Debt [Line Items]
Total	205,000	205,000
Notes Payable Five [Member]
Short-term Debt [Line Items]
Total	150,000	150,000
Notes Payable Six [Member]
Short-term Debt [Line Items]
Total	116,800	116,800
Notes Payable Seven [Member]
Short-term Debt [Line Items]
Total		454,032
Notes payable							$ 425,000
Notes Payable Eight [Member]
Short-term Debt [Line Items]
Total	105,500	105,500
Notes Payable Nine [Member]
Short-term Debt [Line Items]
Total	47,975	47,975
Notes Payable Ten [Member]
Short-term Debt [Line Items]
Total	65,000	65,000
Warrant exercise price per share						$ 5
Notes Payable Eleven [Member]
Short-term Debt [Line Items]
Total	118,000	118,000
Warrant exercise price per share						$ 0.05
Notes Payable Twelve [Member]
Short-term Debt [Line Items]
Total	323,855	323,855
Notes Payable Twelve [Member] | Maximum [Member]
Short-term Debt [Line Items]
Warrant exercise price per share					$ 40
Notes Payable Thirteen [Member]
Short-term Debt [Line Items]
Total	23,000	23,000
Notes Payable Fourteen [Member]
Short-term Debt [Line Items]
Total	231,478	231,478
Notes Payable Fifteen [Member]
Short-term Debt [Line Items]
Total	10,000	10,000
Warrant exercise price per share			$ 5	$ 5
Notes Payable Sixteen [Member]
Short-term Debt [Line Items]
Total	150,000	150,000
Notes Payable Seventeen [Member]
Short-term Debt [Line Items]
Total		53,000
Notes Payable Eightteen [Member]
Short-term Debt [Line Items]
Total	$ 697,600

Notes payable (Details Narrativ

Notes payable (Details Narrative) - USD ($)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Jun. 30, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Notes payable			$ 3,070,208	$ 2,879,640
Accrued unpaid interest and default penalties			485,915	635,217
Promissory Notes [Member]
Short-term Debt [Line Items]
Number of common shares issued	5,402	6,893
Shares issued, price per share	$ 10.40	$ 8.15
Debt conversion, original amount	$ 53,000	$ 53,000
Debt, accrued interest	$ 3,480	$ 3,180
Shareholders [Member]
Short-term Debt [Line Items]
Notes payable			$ 1,677,275	$ 1,639,275

Schedule of Reconciliation of C

Schedule of Reconciliation of Changes in the Fair Value of Derivative Liabilities (Details)	6 Months Ended
	Jun. 30, 2021USD ($)
Derivative Liabilities
Balance December 31, 2020	$ 1,254,441
Change in fair value	21,899
Settlement of liability upon debt exchange and conversion	(1,276,340)
Balance June 30, 2021

Derivative Liabilities (Details

Derivative Liabilities (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Dec. 31, 2020
Schedule of Capitalization, Long-term Debt [Line Items]
Derivative liabilities			$ 1,254,444
Non-convertible promissory notes	$ 3,070,208		$ 2,879,640
Issuance of common stock upon conversion of debt, shares	5,402
Issuance of common stock upon conversion of debt	$ 56,480
Change in fair value	21,899
Extinguishment of derivative liability upon conversion of debt	$ 76,211
Non-Convertible Promissory Notes [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Derivative liabilities		$ 1,200,129
Non-convertible promissory notes		$ 697,600

Schedule of Outstanding Common

Schedule of Outstanding Common Stock Warrants (Details)	Jun. 30, 2021$ / sharesshares
Class of Warrant or Right [Line Items]
Number of Shares | shares	20,062,623
Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 5
Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 200
Third Quarter 2021 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	5,167
Remaining Life (years)	6 months
Third Quarter 2021 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 30
Third Quarter 2021 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 200
Fourth Quarter 2021 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	300
Exercise Price	$ 100
Remaining Life (years)	9 months
First Quarter 2022 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	150
Exercise Price	$ 200
Remaining Life (years)	1 year
Second Quarter 2022 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	1,750
Exercise Price	$ 150
Remaining Life (years)	1 year 3 months
Third Quarter 2022 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	1,650
Remaining Life (years)	1 year 6 months
Third Quarter 2022 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 50
Third Quarter 2022 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 100
Fourth Quarter 2022 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	9,811
Remaining Life (years)	1 year 9 months
Fourth Quarter 2022 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 80
Fourth Quarter 2022 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 290
First Quarter 2023 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	1,204,000
Remaining Life (years)	2 years
First Quarter 2023 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 5
First Quarter 2023 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 40
Second Quarter 2023 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	802,000
Remaining Life (years)	2 years 3 months
Second Quarter 2023 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 5
Second Quarter 2023 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 200
Third Quarter 2023 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	7,521,500
Remaining Life (years)	2 years 6 months
Third Quarter 2023 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 5
Third Quarter 2023 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 100
Fourth Quarter 2023 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	6,024,300
Fourth Quarter 2023 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 0.20
Fourth Quarter 2023 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 5
Fourth Quarter 2023 [Member]
Class of Warrant or Right [Line Items]
Remaining Life (years)	2 years 9 months
First Quarter 2024 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	3,660,000
Exercise Price	$ 5
First Quarter 2024 [Member]
Class of Warrant or Right [Line Items]
Remaining Life (years)	3 years
Second Quarter 2024 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	800,000
Exercise Price	$ 5
Remaining Life (years)	3 years 3 months
Third Quarter 2028 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	3,000
Exercise Price	$ 70
Remaining Life (years)	7 years 6 months
Fourth Quarter 2024 [Member]
Class of Warrant or Right [Line Items]
Number of Shares | shares	28,995
Remaining Life (years)	11 years 3 months
Fourth Quarter 2024 [Member] | Minimum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 10
Fourth Quarter 2024 [Member] | Maximum [Member]
Class of Warrant or Right [Line Items]
Exercise Price	$ 70

Schedule of Outstanding Stock W

Schedule of Outstanding Stock Warrants (Details) - $ / shares	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Number of Shares Warrants, Ending balance	20,062,623	20,081,035
Weighted Average Price, Beginning balance	$ 0.68
Number of Shares Warrants, Issued
Exercise Price, Issued
Weighted Average Price, Issued
Number of Shares Warrants, Expired and forfeited	(18,412)
Weighted Average Price, Expired and forfeited	$ 152.68
Number of Shares Warrants, Exercised
Exercise Price, Exercised
Weighted Average Price, Exercised
Weighted Average Price, Ending balance	0.54
Minimum [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Exercise Price, Beginning balance	0.05
Exercise Price, Expired and forfeited	14
Exercise Price, Ending balance	0.05
Maximum [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Exercise Price, Beginning balance	200
Exercise Price, Expired and forfeited	200
Exercise Price, Ending balance	$ 200

Capital Structure _ Common St_3

Capital Structure – Common Stock and Stock Purchase Warrants (Details Narrative) - USD ($)	Jun. 30, 2021	Jun. 30, 2020
Capital Structure Common Stock And Stock Purchase Warrants
Number of warrants issued during period	0	0
Modification of warrant issued	$ 0

Income Taxes _ Results of Ope_2

Income Taxes – Results of Operations (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Income Tax Disclosure [Abstract]
Income tax expense	$ 0
Statutory income tax rate	21.00%	21.00%

Schedule of Consideration (Deta

Schedule of Consideration (Details) - USD ($)	May 13, 2020	Feb. 28, 2020
Forte Biotechnology International Corp [Member]
Entity Listings [Line Items]
Notes in Default		$ 1,742,868
Accounts payable and accruals		245,692
Past Due Employee Obligations		1,016,648
Total Consideration to be Recognize Upon Execution		$ 3,005,208
Cytocom Inc., [Member]
Entity Listings [Line Items]
Notes in Default	$ 3,302,209
Accounts payable and accruals	230,000
Past Due Employee Obligations	1,110,567
Total Consideration to be Recognize Upon Execution	1,340,567
Total anticipated Consideration	4,642,776
Recognized through December 31, 2020	$ (3,302,209)

Schedule of Royalty Rate (Detai

Schedule of Royalty Rate (Details)	Feb. 27, 2020
Less than $500,000,000 [Member]
Multiemployer Plan [Line Items]
Royalty Rate	2.00%
500,000,000 to Less than $1,000,000,000 [Member]
Multiemployer Plan [Line Items]
Royalty Rate	4.00%
Greater than $1,000,000,000 [Member]
Multiemployer Plan [Line Items]
Royalty Rate	6.00%

Licenses Agreements (Details Na

Licenses Agreements (Details Narrative) - USD ($)	Feb. 27, 2020	Jun. 30, 2021
Cato Research Ltd [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Outstanding accounts payable		$ 372,732
Penn State University [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Outstanding accounts payable		$ 421,048
License Agreement [Member] | Forte Biotechnology International Corp [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Non-refundable milestone payments	$ 100,000
Royalty term	15 years